Abstract:Cancer is a perilous life-threatening disease, and attempts are constantly made to create multinuclear transition metal complexes that could lead to potential anticancer medications and administration procedures. Hence, this work aims to design, synthesize, characterize, and assess the anticancer efficacy of ruthenium p-cymene complexes incorporating N, N'- bis(4-substituted benzoyl)hydrazine ligands. The formation of the new complexes (Ru2H1-Ru2H3) has been thoroughly established by elemental analysis, FT-IR, UV-vis, NMR, and HR-MS spectral techniques. The solid-state molecular structures of the complexes Ru2H1 and Ru2H3 have been determined using the SC-XRD study, which confirms the N, O, and Cl-legged piano stool pseudo-octahedral geometry on each ruthenium(II) ion. The stability of these complexes in the solution state and their lipophilicity profile have been determined. Further, the titled complexes were tested for their in vitro anticancer activity against the cancerous H460 (lung cancer cells), SkBr3 (breast cancer cells), HepG2 (liver cancer cells), and Hela (cervical cancer cells) along with non-cancerous (HEK-293) cells. The IC50 results revealed that complex Ru2H3 exhibits potent activity against the proliferation of all four cancer cells and outscored the effect of standard metallodrug cisplatin. This may be attributed to the presence of a couple of lipophilic electron-donating methoxy groups in the ligand scaffold and also the ruthenium(II) p-cymene motifs. Advantageously, all the complexes (Ru2H1-Ru2H3) displayed cytotoxic specificity only towards the cancerous cell by leaving the off-target non-cancerous cells undamaged. Acridine orange/ethidium bromide (AO/EB) staining, Hoechst 33342, Mitochondrial Membrane Potential (MMP), and Reactive Oxygen Species (ROS) staining assays were used to investigate the apoptotic pathway and ROS levels in mitochondria. The results of Western blot analysis confirmed that complexes triggered apoptosis through intrinsic mitochondrial pathway by upregulating Bax and downregulating Bcl-2 proteins. Finally, the extent of apoptosis triggered by complex (Ru2H3) was quantified with the aid of flow cytometry using the Annexin V-FITC/propidium iodide (PI) double-staining technique.

Exploring the Cytotoxicity of Dinuclear Ru(II) p-cymene Complexes Appended N,N'-Bis(4-substituted benzoyl)hydrazines: Insights into the Mechanism of Apoptotic Cell Death

Dinuclear arene ruthenium(II) arylthiourea complexes: Synthesis, structure, cancer cell growth inhibition and apoptosis induction studies

Cytotoxicity in vitro, cellular uptake, localization and apoptotic mechanism studies induced by ruthenium(II) complex

Cyclometalated Ru(II)-NHC Complexes with Phenanthroline Ligand Induce Apoptosis Mediated by Mitochondria and Endoplasmic Reticulum Stress in Cancer Cells

Synthesis, characterization, and anticancer activity of Ru( p -cymene) complexes bearing pyrazolyl–pyridine type ligands

Ruthenium p-Cymene Complexes Incorporating Substituted Pyridine-Quinoline-Based Ligands: Synthesis, Characterization, and Cytotoxic Properties

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

The induction of mitochondria-mediated apoptosis in cancer cells by ruthenium(II) asymmetric complexes.

A comparative study on in vitro cytotoxicity, cellular uptake, localization and apoptosis-inducing mechanism of two ruthenium(II) complexes

Design, synthesis and anticancer evaluation of novel half-sandwich Ru(II) complexes bearing pyrazalone moiety: Apoptosis inducers based on mitochondrial dysfunction and G0/G1 arrest

Anticancer Activity of Bifunctional Organometallic Ru(II) Arene Complexes Containing a 7-Hydroxycoumarin Group

Synthesis, Characterization, Cellular Uptake and Apoptosis-Inducing Properties of Two Highly Cytotoxic Cyclometalated Ruthenium(ii) Β-Carboline Complexes.

Selective anticancer activities of ruthenium(II)-tetrazole complexes and their mechanistic insights

Ruthenium Complexes with Phenylterpyridine Derivatives Target Cell Membrane and Trigger Death Receptors-Mediated Apoptosis in Cancer Cells.

Ruthenium Complexes Containing 2,6-Bis(benzimidazolyl)pyridine Derivatives Induce Cancer Cell Apoptosis by Triggering Dna Damage-Mediated P53 Phosphorylation

Mixed-ligand ruthenium polypyridyl complexes as apoptosis inducers in cancer cells, the cellular translocation and the important role of ROS-mediated signaling.

Mitochondria Are the Primary Target in the Induction of Apoptosis by Chiral Ruthenium(ii) Polypyridyl Complexes in Cancer Cells

Ruthenium Polypyridyl Complexes That Induce Mitochondria-Mediated Apoptosis In Cancer Cells

Synthesis, characterization, and anticancer activity of ruthenium(II)-β-carboline complex.

Investigation of Inducing Apoptosis in Human Lung Cancer A549 Cells and Related Mechanism of a Ruthenium(ii) Polypyridyl Complex

Systematic evaluation of the antitumor activity of three ruthenium polypyridyl complexes